善水科技 reported revenue of ¥0.48B for the period ended 2026-06-30, +56.4% year on year. Net income was ¥0.09B, a 17.8% net margin on a 34.4% gross margin. The largest revenue line is 氯代吡啶系列产品 at 53% of the total. Free cash flow for the period was ¥0.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.48B | +56.4% |
| Gross profit | ¥0.16B | — |
| Operating income | ¥0.10B | — |
| Net income | ¥0.09B | +78.2% |
| Gross margin | 34.4% | Net margin 17.8% |
| Revenue Q/Q | +31.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 氯代吡啶系列产品 | ¥0.25B | 52.8% |
| 6-硝体、氧体 | ¥0.18B | 37.6% |
| 其他产品 | ¥0.05B | 9.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.31B | 65.6% |
| R&D | ¥0.02B | 4.2% |
| SG&A | ¥0.04B | 8.6% |
| Tax & other | ¥0.01B | 2.4% |
| Item | Amount |
|---|---|
| Total assets | ¥2.24B |
| Total liabilities | ¥0.24B |
| Shareholders' equity | ¥2.00B |
| Equity / assets | 89.2% |
| Operating cash flow | ¥0.09B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.04B |
| Cash conversion (OCF / net income) | 45% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
菲菱科思 ・ 泰祥股份 ・ 家联科技 ・ 北路智控 ・ 唯科科技 ・ 工大科雅 ・ 喜悦智行 ・ 迈赫股份 ・ 大族数控 ・ 诚达药业 ・ 朗威股份 ・ 国泰环保
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies